Please assess the completion status of the following clinical trial:

Trial Title: Diclofenac for Submassive PE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute symptomatic PE confirmed by multidetector CT angiography, a high-probability V/Q scan, or by the presence of deep vein thrombosis confirmed by lower limb ultrasound testing in patients with nonconclusive V/Q scan;~2. first symptoms occurring ten days or less before randomization;~3. haemodynamic stability (systolic blood pressure \> 100 mm Hg, no need of inotropic support, pulmonary resuscitation, intubation or thrombolytic treatment);~4. right ventricular dysfunction assessed by transthoracic echocardiography within the first 12 hours after diagnosis of PE;~5. signed informed consent.~Exclusion Criteria:~1. Previous diagnosis of chronic thromboembolic pulmonary hypertension;~2. active bleeding, or clinically relevant bleeding in the previous month before diagnosis of PE;~3. peptic ulcer;~4. major surgery, or severe trauma in the previous month before diagnosis of PE;~5. indication for chronic anticoagulation;~6. pregnancy or breast feeding;~7. renal insufficiency (serum creatinine \> 2 mg/dL) or severe hepatic impairment;~8. hypersensitivity to diclofenac, sodium metabisulfite, or acetylsalicylic acid;~9. bronchial asthma;~10. severe congestive heart failure;~11. inflammatory bowel disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diclofenac (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).